Application Of Levosimendan Under PICCO In ACS With Acute Heart Failure Syndrome

Objective: To study the clinical effect,adverse reactions and prognosis of levosimendan as an adjuvant therapy for ACS patients with acute heart failure under PICCO monitoring.Methods: A total of 88 patients with ACS and AHF were prepared according to the inclusion and exclusion criteria.A total of 88 patients were studied by PICCO.Through clinical observation,the experimental group with levosimendan and the control group without levosimendan were evaluated by PICCO for hemodynamic changes in the two groups,and the treatment of levosimendan was evaluated.Results: Comparison of various indicators before and after treatment in the two groups of patients with PCI.The ejection fraction after treatment was higher in the experimental group than before treatment,and BNP and heart rate were lower than those in the control group(P <0.05).CI,SVI,dPmax,and GEF were higher than before treatment,and SVRI,ITBV,EVLW,and GEDV were decreased,which had significant effects compared with the control group(P <0.05).And through clinical discovery,the experimental group had fewer days of hospitalization compared with the control group,and the difference in statistical results was statistically significant(P <0.05).Comparison of various indicators before and after treatment in two groups of patients without PCI.After treatment,CKMB,BNP,and heart rate were lower than before treatment,compared with the control group(P <0.05).CI,SVI,dPmax,and GEF were lower in the test group after treatment SVRI and GEDV decreased before the treatment,which was significantly different from the control group(P <0.05).The number of days of hospitalization in the experimental group was significantly reduced compared to the control group,and the number of deaths in the hospital was also decreased compared to the control group.The statistical difference was statistically significant(P <0.05).Therefore,the relevant conclusions are as follows: Through clinical treatment,it was found that levosimendan can clinically regulate blood flow disorders and cardiac function-related problems in patients with ACS and AHF,and at the same time,it can reduce the length of hospital stay and improve the condition.effect.And clinical studies have found that the drug has little effect on liver,kidney function,and potassium of patients.